WCN26-3501 EVALUATION OF PATHOPHYSIOLOGY BIOMARKERS IN KIDNEY BIOPSIES COLLECTED IN IMAgINATION, A PHASE 3 STUDY OF SEFAXERSEN IN PATIENTS WITH IgA NEPHROPATHY

Read full text Summarise with VIRAT
Authors: Jonathan Barratt, Loreto Gesualdo, Dana V. Rizk, Hua Li, Irene L. Noronha, Vishal Duggal, Nadine Schmit, Nikhil Kamath, Amanda Nash, Naron Sasenarine, Chang Liu, Jeannette Lo
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The complement alternative pathway (AP) has been implicated in the pathogenesis of IgA nephropathy (IgAN) and increased activity of Factor B (FB), a key mediator of the AP, is associated with poorer kidney outcomes. Mesangial deposition of IgA and complement, including AP proteins, is often observed in the diagnostic biopsy but there is limited understanding of in situ changes during disease progression or treatment. Sefaxersen (RO7434656, IONIS-FB-LRx), an antisense oligonucleotide (ASO) against FB, is the first AP mRNA-targeting therapy in late-stage development for the treatment of IgAN6.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Complement system in diseases Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104441–104441
Publication date
25 March 2026
Language
EN